Current Status of Liquid Biopsies for the Detection and Management of Prostate Cancer

Overview

Journal Cancer Manag Res

Publisher Dove Medical Press

Specialty Oncology

Date 2019 Jun 27

PMID 31239778

Citations 35

Authors

Yi-Tsung Lu

Kevin Delijani

Andrew Mecum

Amir Goldkorn

Affiliations

Soon will be listed here.

Abstract

In recent years, new therapeutic options have become available for prostate cancer (PC) patients, generating an urgent need for better biomarkers to guide the choice of therapy and monitor treatment response. Liquid biopsies, including circulating tumor cells (CTCs), circulating nucleic acids, and exosomes, have been developed as minimally invasive assays allowing oncologists to monitor PC patients with real-time cellular or molecular information. While CTC counts remain the most extensively validated prognostic biomarker to monitor treatment response, recent advances demonstrate that CTC morphology and androgen receptor characterization can provide additional information to guide the choice of treatment. Characterization of cell-free DNA (cfDNA) is another rapidly emerging field with novel technologies capable of monitoring the evolution of treatment relevant alterations such as those in DNA damage repair genes for poly (ADP-ribose) polymerase (PARP) inhibition. In addition, several new liquid biopsy fields are emerging, including the characterization of heterogeneity, CTC RNA sequencing, the culture and xenografting of CTCs, and the characterization of extracellular vesicles (EVs) and circulating microRNAs. This review describes the clinical utilization of liquid biopsies in the management of PC patients and emerging liquid biopsy technologies with the potential to advance personalized cancer therapy.

Citing Articles

Fusion MRI/Ultrasound-Guided Transperineal Biopsy: A Game Changer in Prostate Cancer Diagnosis.

Giannakodimos I, Kaltsas A, Moulavasilis N, Kratiras Z, Mitropoulos D, Chrisofos M J Clin Med. 2025; 14(2).

PMID: 39860459 PMC: 11765810. DOI: 10.3390/jcm14020453.

Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer.

Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J JAMA Netw Open. 2024; 7(10):e2437871.

PMID: 39374015 PMC: 11581504. DOI: 10.1001/jamanetworkopen.2024.37871.

Liquid Biopsy in the Clinical Management of Cancers.

Ho H, Chung K, Kan C, Wong S Int J Mol Sci. 2024; 25(16).

PMID: 39201281 PMC: 11354853. DOI: 10.3390/ijms25168594.

Prostate cancer genotyping for risk stratification and precision treatment.

Kumar A Curr Urol. 2024; 18(2):87-97.

PMID: 39176294 PMC: 11337998. DOI: 10.1097/CU9.0000000000000222.

UPCARE: Urinary Extracellular Vesicles-Derived Prostate Cancer Assessment for Risk Evaluation.

Jiang S, Lu F, Chen J, Jiao Y, Qiu Q, Nian X J Extracell Vesicles. 2024; 13(8):e12491.

PMID: 39175282 PMC: 11341834. DOI: 10.1002/jev2.12491.

References

Vona G, Sabile A, Louha M, Sitruk V, Romana S, Schutze K . Isolation by size of epithelial tumor cells : a new method for the immunomorphological and molecular characterization of circulatingtumor cells. Am J Pathol. 2000; 156(1):57-63. PMC: 1868645. DOI: 10.1016/S0002-9440(10)64706-2. View

. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69(3):89-95. DOI: 10.1067/mcp.2001.113989. View

Klein C, Seidl S, Petat-Dutter K, Offner S, Geigl J, Schmidt-Kittler O . Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol. 2002; 20(4):387-92. DOI: 10.1038/nbt0402-387. View

Dressman D, Yan H, Traverso G, Kinzler K, Vogelstein B . Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003; 100(15):8817-22. PMC: 166396. DOI: 10.1073/pnas.1133470100. View

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Smirnov D, Zweitzig D, Foulk B, Miller M, Doyle G, Pienta K . Global gene expression profiling of circulating tumor cells. Cancer Res. 2005; 65(12):4993-7. DOI: 10.1158/0008-5472.CAN-04-4330. View

Epstein J, Allsbrook Jr W, Amin M, Egevad L . The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2005; 29(9):1228-42. DOI: 10.1097/01.pas.0000173646.99337.b1. View

Diehl F, Li M, He Y, Kinzler K, Vogelstein B, Dressman D . BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006; 3(7):551-9. DOI: 10.1038/nmeth898. View

Gutman S, Kessler L . The US Food and Drug Administration perspective on cancer biomarker development. Nat Rev Cancer. 2006; 6(7):565-71. DOI: 10.1038/nrc1911. View

10.

Antonatos D, Patsilinakos S, Spanodimos S, Korkonikitas P, Tsigas D . Cell-free DNA levels as a prognostic marker in acute myocardial infarction. Ann N Y Acad Sci. 2006; 1075:278-81. DOI: 10.1196/annals.1368.037. View

11.

Cheruvanky A, Zhou H, Pisitkun T, Kopp J, Knepper M, Yuen P . Rapid isolation of urinary exosomal biomarkers using a nanomembrane ultrafiltration concentrator. Am J Physiol Renal Physiol. 2007; 292(5):F1657-61. PMC: 2271070. DOI: 10.1152/ajprenal.00434.2006. View

12.

Stephenson A, Scardino P, Kattan M, Pisansky T, Slawin K, Klein E . Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25(15):2035-41. PMC: 2670394. DOI: 10.1200/JCO.2006.08.9607. View

13.

Danila D, Heller G, Gignac G, Gonzalez-Espinoza R, Anand A, Tanaka E . Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res. 2007; 13(23):7053-8. DOI: 10.1158/1078-0432.CCR-07-1506. View

14.

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

15.

Raj A, Bogaard P, Rifkin S, van Oudenaarden A, Tyagi S . Imaging individual mRNA molecules using multiple singly labeled probes. Nat Methods. 2008; 5(10):877-9. PMC: 3126653. DOI: 10.1038/nmeth.1253. View

16.

de Bono J, Scher H, Montgomery R, Parker C, Miller M, Tissing H . Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res. 2008; 14(19):6302-9. DOI: 10.1158/1078-0432.CCR-08-0872. View

17.

Maher C, Kumar-Sinha C, Cao X, Kalyana-Sundaram S, Han B, Jing X . Transcriptome sequencing to detect gene fusions in cancer. Nature. 2009; 458(7234):97-101. PMC: 2725402. DOI: 10.1038/nature07638. View

18.

Scher H, Jia X, de Bono J, Fleisher M, Pienta K, Raghavan D . Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol. 2009; 10(3):233-9. PMC: 2774131. DOI: 10.1016/S1470-2045(08)70340-1. View

19.

Talasaz A, Powell A, Huber D, Berbee J, Roh K, Yu W . Isolating highly enriched populations of circulating epithelial cells and other rare cells from blood using a magnetic sweeper device. Proc Natl Acad Sci U S A. 2009; 106(10):3970-5. PMC: 2645911. DOI: 10.1073/pnas.0813188106. View

20.

Tang F, Barbacioru C, Wang Y, Nordman E, Lee C, Xu N . mRNA-Seq whole-transcriptome analysis of a single cell. Nat Methods. 2009; 6(5):377-82. DOI: 10.1038/nmeth.1315. View